Haleon plc ADR (HLN) is slightly overvalued and Neurocrine Biosciences Inc (NBIX) is undervalued.
Against our estimates of intrinsic value, NBIX trades at the wider discount: a margin of safety of +29%, against -14% for HLN.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $8.10; the price of $9.25 is 14% above that value, and 76% of that value comes from beyond year five.
Leak Score 27/100 on 3 of 12 signals
Discounting its cash flows at 7.8% (average of 3 methods) values the shares at $201.20; the price of $142.25 is 29% below that value, and 81% of that value comes from beyond year five.
Leak Score 100/100 on 3 of 12 signals
| Metric | HLN | NBIX |
|---|---|---|
| Verdict | Slightly overvalued | Undervalued |
| Price | $9.25 | $142.25 |
| Intrinsic value | $8.10 | $201.20 |
| Margin of safety | -14% | +29% |
| Leak Score | 27/100 (3/12) | 100/100 (3/12) |
| Market cap | $40.7B | $14.5B |
| Revenue growth, 5 years | 2.8% | 22.3% |
| Operating margin | 23.3% | 23.9% |
| Net margin | 14.6% | 20.9% |
| Return on equity | 10.0% | 22.1% |
| Debt to equity | 0.50 | 0.11 |
| P/E | 19.0x | 20.8x |
| Forward P/E | 15.0x | 14.6x |
| P/B | 1.9x | 3.9x |
| Dividend yield | 2.4% | — |